A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden

被引：3

作者：

Rebeck, Olivia N. ^{[1
,2
]}

Wallace, Miranda J. ^{[1
,2
]}

Prusa, Jerome ^{[1
,2
]}

Ning, Jie ^{[1
,2
]}

Evbuomwan, Esse M. ^{[1
,2
,3
]}

Rengarajan, Sunaina ^{[1
,4
]}

Habimana-Griffin, Lemoyne ^{[1
,5
]}

Kwak, Suryang ^{[1
,2
]}

Zahrah, David ^{[1
]}

Tung, Jason ^{[1
]}

Liao, James ^{[1
,2
]}

Mahmud, Bejan ^{[1
,2
]}

Fishbein, Skye R. S. ^{[1
,2
]}

Tovar, Erick S. Ramirez ^{[1
,2
]}

Mehta, Rehan ^{[1
,2
]}

Wang, Bin ^{[1
,2
]}

Gorelik, Mark G. ^{[1
,2
]}

Helmink, Beth A. ^{[6
]}

Dantas, Gautam ^{[1
,2
,3
,7
,8
]}

机构：

[1] Washington Univ, Sch Med, Edison Family Ctr Genome Sci & Syst Biol, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Dept Pathol & Immunol, Div Lab & Genom Med, St Louis, MO 63110 USA

[3] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA

[4] Washington Univ, Sch Med, John T Milliken Dept Internal Med, Div Dermatol, St Louis, MO 63110 USA

[5] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[7] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA

[8] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA

来源：

CELL CHEMICAL BIOLOGY | 2025年 / 32卷 / 01期

基金：

美国国家卫生研究院;

关键词：

MONOCLONAL-ANTIBODY THERAPY; SACCHAROMYCES-BOULARDII; GUT MICROBIOME; RESISTANCE; CANCER; IMMUNOTHERAPY; MECHANISMS; PREVENTION; EFFICACY;

D O I：

10.1016/j.chembiol.2024.10.013

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Engineered probiotics are an emerging platform for in situ delivery of therapeutics to the gut. Herein, we developed an orally administered, yeast-based therapeutic delivery system to deliver next-generation immune checkpoint inhibitor (ICI) proteins directly to gastrointestinal tumors. We engineered Saccharomyces cerevisiae var. boulardii (Sb), a probiotic yeast with high genetic tractability and innate anticancer activity, to secrete "miniature"antibody variants that target programmed death ligand 1 (Sb_haPD-1). When tested in an ICI-refractory colorectal cancer (CRC) mouse model, Sb_haPD-1 significantly reduced intestinal tumor burden and resulted in significant shifts to the immune cell profile and microbiome composition. This oral therapeutic platform is modular and highly customizable, opening new avenues of targeted drug delivery that can be applied to treat a myriad of gastrointestinal malignancies.

引用

页数：21

共 50 条

[21] Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
Dongxue Liu
Linlin Hu
Hua Shao
Cancer Chemotherapy and Pharmacology, 2023, 92 : 165 - 179
[22] Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
Liu, Dongxue
Hu, Linlin
Shao, Hua
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (03) : 165 - 179
[23] Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Valero, Cristina
Lee, Mark
Hoen, Douglas
Weiss, Kate
Kelly, Daniel W.
Adusumilli, Prasad S.
Paik, Paul K.
Plitas, George
Ladanyi, Marc
Postow, Michael A.
Ariyan, Charlotte E.
Shoushtari, Alexander N.
Balachandran, Vinod P.
Hakimi, A. Ari
Crago, Aimee M.
Roche, Kara C. Long
Smith, J. Joshua
Ganly, Ian
Wong, Richard J.
Patel, Snehal G.
Shah, Jatin P.
Lee, Nancy Y.
Riaz, Nadeem
Wang, Jingming
Zehir, Ahmet
Berger, Michael F.
Chan, Timothy A.
Seshan, Venkatraman E.
Morris, Luc G. T.
NATURE COMMUNICATIONS, 2021, 12 (01)
[24] Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer
Popat, Vinita
Lu, Rong
Ahmed, Murtaza
Park, Jason Y.
Xie, Yang
Gerber, David E.
ONCOLOGIST, 2020, 25 (06): : 515 - 522
[25] Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Cristina Valero
Mark Lee
Douglas Hoen
Kate Weiss
Daniel W. Kelly
Prasad S. Adusumilli
Paul K. Paik
George Plitas
Marc Ladanyi
Michael A. Postow
Charlotte E. Ariyan
Alexander N. Shoushtari
Vinod P. Balachandran
A. Ari Hakimi
Aimee M. Crago
Kara C. Long Roche
J. Joshua Smith
Ian Ganly
Richard J. Wong
Snehal G. Patel
Jatin P. Shah
Nancy Y. Lee
Nadeem Riaz
Jingming Wang
Ahmet Zehir
Michael F. Berger
Timothy A. Chan
Venkatraman E. Seshan
Luc G. T. Morris
Nature Communications, 12
[26] Yeast-based nucleotide supplementation in mother sows modifies the intestinal barrier function and immune response of neonatal pigs
Lumin Gao
Chunyan Xie
Xiaoxiao Liang
Zhihong Li
Biao Li
Xin Wu
Yulong Yin
Animal Nutrition, 2021, 7 (01) : 84 - 93
[27] Yeast-based nucleotide supplementation in mother sows modifies the intestinal barrier function and immune response of neonatal pigs
Gao, Lumin
Xie, Chunyan
Liang, Xiaoxiao
Li, Zhihong
Li, Biao
Wu, Xin
Yin, Yulong
ANIMAL NUTRITION, 2021, 7 (01): : 84 - 93
[28] The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
Cortellini, Alessio
JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
[29] Personalized mRNA cancer vaccines with immune checkpoint inhibitors: A promising therapeutic approach in oral cancer patients
Gheena, Sukumaran
Ezhilarasan, Devaraj
ORAL ONCOLOGY, 2023, 137
[30] The effect of tumor mutation burden on immune checkpoint inhibitors in non-small cell lung cancer.
Zhao, Jie
Dong, Yiting
Bai, Hua
Duan, Jianchun
Wang, Guoqiang
Xu, Jiachen
Wang, Zhijie
Wang, Jie
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →